Cephalalgia : an international journal of headache
-
Randomized Controlled Trial Multicenter Study Controlled Clinical Trial
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of episodic migraine. ⋯ Eptinezumab (100 mg or 300 mg) significantly reduced migraine frequency, was well tolerated, and had an acceptable safety profile when used for the preventive treatment of migraine in adults with episodic migraine. ClinicalTrials.gov identifier: NCT02559895.